Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.

How can pharmaceutical firms shore up their sustainability credentials at a time when the entire research landscape is turning on its head? A recent webinar from supply chain leaders World Courier and ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...